Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EBITDA: 2023-2025

Historic EBITDA for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's EBITDA fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
  • Latest data reveals that Immunome reported EBITDA of -$60.1 million as of Q3 2025, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's EBITDA peaked at -$4.5 million during Q1 2023, and registered a low of -$132.3 million during Q1 2024.
  • Its 3-year average for EBITDA is -$51.5 million, with a median of -$46.5 million in 2025.
  • Per our database at Business Quant, Immunome's EBITDA slumped by 2,859.05% in 2024 and then soared by 66.26% in 2025.
  • Over the past 3 years, Immunome's EBITDA (Quarterly) stood at -$94.7 million in 2023, then climbed by 12.34% to -$83.0 million in 2024, then decreased by 19.03% to -$60.1 million in 2025.
  • Its EBITDA was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.